A new amplification assay from a Chinese regulator academic vendor team turns a culture based Mycoplasma release test into a same day screen, with explicit trade offs the senior author is candid about.
A cell therapy batch sitting in a release queue has roughly the shelf life of a head of lettuce. The Mycoplasma contamination test that stands between that batch and the patient still takes up to 28 days under the traditional culture and indicator-cell method recommended by older pharmacopoeia chapters, and the cell product often expires long before the result lands. A team anchored by China's National Institute for Food and Drug Control (NIFDC), the vendor Yeasen Biotechnology, and Xi'an Jiaotong-Liverpool University has now published a nucleic acid amplification test (NAAT) that collapses that wait to a few hours, as reported by Genetic Engineering and Biotechnology News and detailed in the peer-reviewed paper in MDPI Molecules (2026, 31, 1794).
The operational lever is straightforward. NAATs are already recommended by the U.S., EU, and Japanese pharmacopoeias as an alternative to 28-day culture and indicator-cell methods for in-process and release testing of biological products, which is why the new assay was designed to drop onto existing qPCR platforms without special equipment. In a biologics QC lab, the difference between a same-day screen and a four-week culture is not just speed; it is the difference between releasing a short-shelf-life recombinant protein, monoclonal antibody, or autologous cell therapy batch inside its expiry window, or scrapping it.
The assay itself targets Mycoplasma-specific conserved regions with three pairs of primer-probe sets, covering 183 Mollicutes species in a design intended to close the rare-strain detection gap in mainstream multiplex NAATs. Single-copy sensitivity was validated against 10 pharmacopoeia standard strains, and specificity was checked against 14 non-Mycoplasma genera and 6 engineered cell lines. Amplicons sit at 100 to 200 base pairs, amplification efficiency runs 95 to 105 percent, and repeatability was strong, according to the GEN write-up of the MDPI Molecules study. The authors position the test for raw material screening, cell bank verification, and finished product release, and frame it as compatible with Chinese and European pharmacopoeia strain detection requirements.
Xiaoliang Sun, a scientist in the genomics division at Yeasen Biotechnology and the paper's senior author, told GEN that the assay is designed to "optimize the core pain points of mainstream multiplex NAATs" rather than replace them. That framing matters. The two pain points he is pointing at are the trade-off between broad species coverage and analytical sensitivity that has long constrained single-plex Mycoplasma molecular tests, and the regulatory pressure to keep detection rapid as cell and gene therapy batches multiply. Sun's recommendation to readers is to use the new assay as an initial screen and confirm positives with digital PCR, which is the same conservative workflow most quality teams would build around a fast molecular screen.
The candid admission in the paper is that the new design does not erase that coverage-versus-sensitivity trade-off. The authors note that detection performance for unrecorded Mycoplasma strains from extreme environments and highly variable subspecies has not yet been verified, which is a real residual gap rather than a marketing footnote. They also flag that the move from one to three primer-probe sets raises per-sample reagent cost, without putting a number on it. For a QC director, that is a useful trade-off to surface: faster turnaround and broader Mollicutes coverage in exchange for a higher reagent line item on each release test, against the cost of a scrapped autologous batch or a delayed monoclonal antibody shipment.
Three caveats should travel with the speed claim. First, pharmacopoeia "recommendation" of NAAT is not the same as universal regulatory approval for every product class; uptake still varies by indication, region, and inspector. Second, the evidence base is one paper, and the senior author is employed by the company commercializing the assay, a commercial-interest disclosure that belongs in any procurement conversation. Third, there is no published head-to-head performance or cost comparison against widely adopted FDA-approved Mycoplasma NAAT kits from competitors such as BioFire, Lonza, Roche, or Sartorius, so claims about market displacement would outrun the evidence.
What to watch next is whether independent labs replicate the 183-species coverage and the single-copy sensitivity on the standard strains, whether the unrecorded-strain gap gets quantified in a follow-up study, and whether the reagent-cost premium is published in a form a QC budget owner can model. The 28-day clock has not been eliminated; it has been moved off the critical path for the products that can least afford to wait for it.